Support for the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families.
暂无分享,去创建一个
Carl Baker | Santhosh Girirajan | Michael O Dorschner | Evan E Eichler | Jeremy Wechsler | C. Baker | E. Eichler | O. Korvatska | K. Roche | M. Dorschner | S. Girirajan | D. Tsuang | M. Horwitz | A. Timms | R. Kirkwood | Debby W Tsuang | Olena Korvatska | Andrew E Timms | Marshall S Horwitz | Katherine W Roche | Kyu Yeong Choi | Robert Kirkwood | J. Wechsler | Kyu-Yeong Choi | Carl A. Baker
[1] R. Sweet,et al. Genetics of psychosis in Alzheimer's disease: a review. , 2010, Journal of Alzheimer's disease : JAD.
[2] Thomas W. Mühleisen,et al. Large recurrent microdeletions associated with schizophrenia , 2008, Nature.
[3] K. Kanuma,et al. Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia. , 2010, Recent patents on CNS drug discovery.
[4] Janet B W Williams,et al. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[5] D. Blackwood,et al. The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia , 2001, Molecular Psychiatry.
[6] Pablo V Gejman,et al. Genetics of schizophrenia: new findings and challenges. , 2011, Annual review of genomics and human genetics.
[7] M. Constantine‐Paton,et al. Receptor compartmentalization and trafficking at glutamate synapses: a developmental proposal , 2004, Trends in Neurosciences.
[8] M. Geyer,et al. Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors , 2004, Molecular Psychiatry.
[9] E. Walker,et al. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[10] G. Bu,et al. LRP in Amyloid‐β Production and Metabolism , 2006 .
[11] E. Eichler,et al. Phenotypic variability and genetic susceptibility to genomic disorders. , 2010, Human molecular genetics.
[12] S. Levy,et al. Exome sequencing supports a de novo mutational paradigm for schizophrenia , 2011, Nature Genetics.
[13] Martin S. Taylor,et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. , 2000, Human molecular genetics.
[14] D. Rujescu,et al. Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. , 2011, Journal of psychiatric research.
[15] A. Andreeva,et al. Protein Ser/Thr phosphatases PPEF interact with calmodulin. , 2002, Biochemical and biophysical research communications.
[16] Y. Pawitan,et al. A new paradigm emerges from the study of de novo mutations in the context of neurodevelopmental disease , 2013, Molecular Psychiatry.
[17] Joseph A. Gogos,et al. Strong association of de novo copy number mutations with sporadic schizophrenia , 2008, Nature Genetics.
[18] Liam Scott,et al. Role of Thalamic Projection in NMDA Receptor-Induced Disruption of Cortical Slow Oscillation and Short-Term Plasticity , 2011, Front. Psychiatry.
[19] Vance P Lemmon,et al. Kinase/phosphatase overexpression reveals pathways regulating hippocampal neuron morphology , 2010, Molecular systems biology.
[20] Serafim Batzoglou,et al. Identifying a High Fraction of the Human Genome to be under Selective Constraint Using GERP++ , 2010, PLoS Comput. Biol..
[21] Anders D. Børglum,et al. Genome-wide association study identifies five new schizophrenia loci , 2011, Nature Genetics.
[22] S. Nakanishi,et al. Tamalin Is a Scaffold Protein That Interacts with Multiple Neuronal Proteins in Distinct Modes of Protein-Protein Association* , 2003, The Journal of Biological Chemistry.
[23] A. Singleton,et al. Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in Schizophrenia , 2008, Science.
[24] B. Sarg,et al. LRP1b shows restricted expression in human tissues and binds to several extracellular ligands, including fibrinogen and apoE – carrying lipoproteins , 2011, Atherosclerosis.
[25] M. Gill,et al. Replicated genetic evidence supports a role for HOMER2 in schizophrenia , 2010, Neuroscience Letters.
[26] P. Visscher,et al. Rare chromosomal deletions and duplications increase risk of schizophrenia , 2008, Nature.
[27] Eran Halperin,et al. A model based approach for analysis of spatial structure in genetic data , 2013 .
[28] G. Bu,et al. LRP in amyloid-beta production and metabolism. , 2006, Annals of the New York Academy of Sciences.
[29] P. McKenna,et al. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. , 1998, Brain research. Molecular brain research.
[30] Ronak K. Kapadia,et al. Clinically detectable copy number variations in a Canadian catchment population of schizophrenia. , 2010, Journal of psychiatric research.
[31] N. Uranova,et al. Ultrastructural alterations in hippocampal mossy fiber synapses in schizophrenia: A postmortem morphometric study , 2005, Synapse.
[32] Gregory M. Cooper,et al. A Copy Number Variation Morbidity Map of Developmental Delay , 2011, Nature Genetics.
[33] S. Lok,et al. Increased exonic de novo mutation rate in individuals with schizophrenia , 2011, Nature Genetics.
[34] Pall I. Olason,et al. Common variants conferring risk of schizophrenia , 2009, Nature.
[35] Daniel L. Koller,et al. Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction , 2012, Molecular Psychiatry.
[36] K. Roche,et al. Subunit-Specific Regulation of NMDA Receptor Endocytosis , 2004, The Journal of Neuroscience.
[37] J. Coyle,et al. PAGES_DCNS 46_5.qxd:DCNS#45 , 2010 .
[38] Stephen W Scherer,et al. Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease. , 2010, The American journal of psychiatry.
[39] Carlos S. Moreno,et al. Relative Burden of Large CNVs on a Range of Neurodevelopmental Phenotypes , 2011, PLoS genetics.
[40] J. Nurnberger,et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. , 1994, Archives of general psychiatry.
[41] D. Clair,et al. Association within a family of a balanced autosomal translocation with major mental illness , 1990, The Lancet.
[42] S Purcell,et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia , 2011, Molecular Psychiatry.
[43] T. Matise,et al. Genome-wide search for schizophrenia susceptibility loci: the NIMH Genetics Initiative and Millennium Consortium. , 1998, American journal of medical genetics.
[44] M. Tsuang. Genotypes, Phenotypes, and the Brain , 1993, British Journal of Psychiatry.
[45] R. Hammer,et al. Normal Development and Fertility of Knockout Mice Lacking the Tumor Suppressor Gene LRP1b Suggest Functional Compensation by LRP1 , 2004, Molecular and Cellular Biology.
[46] Yonghe Li,et al. The Putative Tumor Suppressor LRP1B, a Novel Member of the Low Density Lipoprotein (LDL) Receptor Family, Exhibits Both Overlapping and Distinct Properties with the LDL Receptor-related Protein* , 2001, The Journal of Biological Chemistry.
[47] W. Danysz,et al. The role of group I metabotropic glutamate receptors in schizophrenia , 2007, Amino Acids.
[48] E M Wijsman,et al. Meta-analysis of 32 genome-wide linkage studies of schizophrenia , 2009, Molecular Psychiatry.
[49] Susanne Walitza,et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder , 2011, Nature Genetics.